Home » Stocks » CRMD

CorMedix, Inc. (CRMD)

Stock Price: $8.96 USD -0.19 (-2.08%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 287.91M
Revenue (ttm) 208,295
Net Income (ttm) -21.24M
Shares Out 32.13M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $8.96
Previous Close $9.15
Change ($) -0.19
Change (%) -2.08%
Day's Open 9.28
Day's Range 8.57 - 9.42
Day's Volume 536,497
52-Week Range 2.35 - 9.42

More Stats

Market Cap 287.91M
Enterprise Value 251.74M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 32.13M
Float n/a
EPS (basic) -0.75
EPS (diluted) -0.79
FCF / Share -0.67
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.00M
Short Ratio 16.33
Short % of Float n/a
Beta 2.39
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,382.21
PB Ratio 8.35
Revenue 208,295
Operating Income -26.51M
Net Income -21.24M
Free Cash Flow -19.96M
Net Cash 36.17M
Net Cash / Share 1.13
Gross Margin -43.19%
Operating Margin -12,728.07%
Profit Margin -10,199.40%
FCF Margin -9,584.41%
ROA -44.94%
ROE -67.25%
ROIC -524.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$15.75*
(75.78% upside)
Low
10.0
Current: $8.96
High
22.0
Target: 15.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.280.430.330.220.210.19----
Revenue Growth-34.09%30.51%46.95%6.65%11.02%9358.97%----
Gross Profit-0.090.030.21-0.14-0.11-0.26-0.20---
Operating Income-21.01-26.86-32.92-24.76-16.65-8.90-4.92-3.00-7.21-8.51
Net Income-16.43-26.83-33.01-24.64-18.19-20.45-9.13-3.38-6.67-10.91
Shares Outstanding24.1517.8211.037.596.274.292.762.282.281.89
Earnings Per Share-1.80-1.51-3.00-3.25-2.90-4.80-3.45-1.50-2.90-5.75
Operating Cash Flow-15.05-23.70-28.59-22.27-12.53-6.32-3.62-2.28-6.30-3.67
Capital Expenditures-0.04-0.05-0.15-0.06-0.02-0.03-0.04---0.01
Free Cash Flow-15.09-23.75-28.74-22.32-12.54-6.35-3.65-2.28-6.30-3.68
Cash & Equivalents28.5117.8012.1620.3435.564.342.590.841.998.28
Total Debt-6.13-----0.27--
Net Cash / Debt28.5111.6712.1620.3435.564.342.590.571.998.28
Assets29.4818.8313.4521.9137.105.102.971.152.568.85
Liabilities5.8313.896.264.093.091.466.991.491.221.59
Book Value23.654.937.1917.8134.013.63-4.02-0.341.337.26
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CorMedix, Inc.
Country United States
Employees 30
CEO Mohammed Khoso Baluch

Stock Information

Ticker Symbol CRMD
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: CRMD
IPO Date March 25, 2010

Description

CorMedix, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.